Effect of human WEE1 and stem cell factor on human CD34+ umbilical cord blood cell damage induced by chemotherapeutic agents

Acta Biochimica et Biophysica Sinica

Volumn 39, Issue 8, 2007, Pages 599-607

  Lei, Ping ^a   He, Yong ^b   Shi, Wenfang ^a   Peng, Jilin ^a,c   Wu, Sha ^a   Zhu, Huifen ^a   Chen, Jianguo ^a   Shen, Guanxin ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Myelosuppression; Radiochemotherapy; SCF; WEE1Hu

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CELL CYCLE PROTEIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; LACTATE DEHYDROGENASE; MITOMYCIN; NUCLEAR PROTEIN; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; UNCLASSIFIED DRUG; WEE1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BLOOD; CELL SURVIVAL; CLONOGENIC ASSAY; DRUG EFFECT; FETUS BLOOD; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; PLASMID; SECRETION;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE PROTEINS; CELL SURVIVAL; CISPLATIN; COLONY-FORMING UNITS ASSAY; DOXORUBICIN; FETAL BLOOD; FLUOROURACIL; HUMANS; L-LACTATE DEHYDROGENASE; MITOMYCIN; NUCLEAR PROTEINS; PLASMIDS; PROTEIN-TYROSINE KINASES; STEM CELL FACTOR; TRANSFECTION;

EID: 34548063761     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2007.00312.x     Document Type: Article

References (31)

1. Carey PJ. Drug-induced myelosuppression: Diagnosis and management. Drug Saf 2003, 26 : 691 706.
2. Sheps JA, Ralph S, Zhao Z, Baillie DL, Ling V. The ABC transporter gene family of Caenorhabditis elegans has implications for the evolutionary dynamics of multidrug resistance in eukaryotes. Genome Biol 2004, 5 : R15.
3. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002, 2 : 48 58.
4. May C, Gunther R, McIvor RS. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood 1995, 86 : 2439 2448.
5. Chan DC, Anderson AC. Towards species-specific antifolates. Curr Med Chem 2006, 13 : 377 398.
6. Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res 1995, 55 : 2608 2614.
7. Kondo S, Yin D, Morimura T, Oda Y, Kikuchi H, Takeuchi J. Transfection with a bcl-2 expression vector protects transplanted bone marrow from chemotherapy-induced myelosuppression. Cancer Res 1994, 54 : 2928 2933.
8. Belzile JP, Karatzas A, Shiu HY, Letourneau S, Palerme JS, Cournoyer D. Increased resistance to nitrogen mustards and antifolates following in vitro selection of murine fibroblasts and primary hematopoietic cells transduced with a bicistronic retroviral vector expressing the rat glutathione S-transferase A3 and a mutant dihydrofolate reductase. Cancer Gene Ther 2003, 10 : 637 646.
9. 14C]carboplatin in human cisplatin-resistant cells results from reduced energy-dependent uptake. J Cell Physiol 2000, 183 : 108 116.
10. Shen D, Pastan I, Gottesman MM. Cross-resistance to methotrexate and metals in human cisplatin-resistant cell lines results from a pleiotropic defect in accumulation of these compounds associated with reduced plasma membrane binding proteins. Cancer Res 1998, 58 : 268 275.
11. Boesen JJ, Nooter K, Valerio D. Circumvention of chemotherapy-induced myelosuppression by transfer of the mdr1 gene. Biotherapy 1993, 6 : 291 302.
12. Schwarzenberger P, Spence S, Lohrey N, Kmiecik T, Longo DL, Murphy WJ, Ruscetti FW et al. Gene transfer of multidrug resistance into a factor-dependent human hematopoietic progenitor cell line: In vivo model for genetically transferred chemoprotection. Blood 1996, 87 : 2723 2731.
13. Banerjee D, Bertino JR. Myeloprotection with drug-resistance genes. Lancet Oncology 2002, 3 : 154 158.
14. Cory S, Huang DC, Adams JM. The Bcl-2 family: Roles in cell survival and oncogenesis. Oncogene 2003, 22 : 8590 8607.
15. Weaver KD, Yeyeodu S, Cusack JC Jr., Baldwin AS Jr., Ewend MG. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 2003, 61 : 187 196.
16. Igarashi M, Nagata A, Jinno S, Suto K, Okayama H. Wee1(+)-like gene in human cells. Nature 1991, 353 : 80 83.
17. Yuan H, Xie YM, Chen IS. Depletion of Wee-1 kinase is necessary for both human immunodeficiency virus type 1 Vpr- and gamma irradiation-induced apoptosis. J Virol 2003, 77 : 2063 2070.
18. Backert S, Gelos M, Kobalz U, Hanski ML, Bohm C, Mann B, Lovin N et al. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int J Cancer 1999, 82 : 868 874.
19. Lotem J, Sachs L. Cytokine control of developmental programs in normal hematopoiesis and leukemia. Oncogene 2002, 21 : 3284 3294.
20. Nakagawa S, Kitoh T. Measurement of KIT ligand/stem cell factor: Clinical and biochemical significance. Curr Opin Hematol 2000, 7 : 133 142.
21. Piacibello W, Sanavio F, Garetto L, Severino A, Bergandi D, Ferrario J, Fagioli F et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997, 89 : 2644 2653.
22. Lei P, Li WH, Liao WJ, Yu B, Zhu HF, Shao JF, Shen GX. Construction and co-expression of bicistronic plasmid encoding human WEE1 and stem cell factor. Acta Biochim Biophys Sin 2005, 37 : 107 112.
23. Vagner S, Galy B, Pyronnet S. Irresistible IRES. Attracting the translation machinery to internal ribosome entry sites. EMBO Rep 2001, 2 : 893 898.
24. Gloeckner H, Jonuleit T, Lemke HD. Monitoring of cell viability and cell growth in a hollow-fiber bioreactor by use of the dye Alamar Blue. J Immunol Methods 2001, 252 : 131 138.
25. Borge OJ, Ramsfjell V, Cui L, Jacobsen SE. Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+CD38- bone marrow cells with multilineage potential at the single-cell level: Key role of thrombopoietin. Blood 1997, 90 : 2282 2292.
26. Hurley LH. Secondary DNA structures as molecular targets for cancer therapeutics. Biochem Soc Trans 2001, 29 : 692 696.
27. Baum C, Kustikova O, Modlich U, Zhixiong LI, Fehse B. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 2006, 17 : 253 263.
28. Sinn PL, Sauter SL, McCray PB Jr. Gene therapy progress and prospects: Development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Therapy 2005, 12 : 1089 1098.
29. Lei P, Yue T, Yu BL, Shen GX. Construction and expression of recombinant gene for fusion of human stem cell factor and EGFP. Med Mol Biol 2004, 1 : 220 223.
30. Wang F, Zhu Y, Huang Y, McAvoy S, Johnson WB, Cheung TH, Chung TK et al. Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis. Oncogene 2005, 24 : 3875 3885.
31. Wang Y, Decker SJ, Sebolt-Leopold J. Knockdown of Chk1, Wee1 and Myt1 by RNA interference abrogates G2 checkpoint and induces apoptosis. Cancer Biol Ther 2004, 3 : 305 313.